Leqvio (inclisiran) / Alnylam, Novartis - LARVOL DELTA

Adherence to statin therapy after inclisiran start, insights from the the DAMAGE registry (ESC-WCC 2025) - No abstract available

Adherence • Cardiovascular

Inclisiran: a breakthrough in LDL-C reduction for indian ASCVD patients (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

First report of Inclisiran therapy in a heart transplanted patient (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Dyslipidemia

Efficacy of inclisiran in patients affected by familial hypercholesterolemia: data from CHOLINET Registry (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Dyslipidemia

Intensified hypolipidaemic therapy with inclisiran for atherosclerotic plaque stabilization (ESC-WCC 2025) - No abstract available

Atherosclerosis • Cardiovascular

Efficacy and safety of inclisiran in patients with and without type 2 diabetes mellitus: a subgroup analysis from the CHOLINET Registry (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Early experience of inclisiran: real-world analysis of utilization and lipid-lowering effects (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular

NLRP3/IL-1 and MyD-88/CCL2 pathway were reduced by inclisiran under exposure to anthracyclines and HER-2 blocking agent (ESC-WCC 2025) - No abstract available

Cardiovascular • CCL2 • HER-2 • NLRP3

Characterization of the pleiotropic effects of Inclisiran (ESC-WCC 2025) - No abstract available

Cardiovascular

Pleiotropic effects of inclisiran on arterial structural and functional parameters (ESC-WCC 2025) - No abstract available

Cardiovascular

VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C (ESC-WCC 2025) - No abstract available

Clinical • Monotherapy • Cardiovascular

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases (clinicaltrials.gov) - P=N/A | N=37688 | Completed | Sponsor: Novartis Pharmaceuticals

New trial • Real-world evidence • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders

Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance. (PubMed, Eur J Neurol) - "The present real-world study highlights the potential therapeutic value of PCSK9 inhibitors and inclisiran among patients with neuromuscular disorders and statin intolerance. The findings of this study are in accordance with previous reports, showing that PCSK9 inhibitors are safe as a lipid lowering treatment for long-term use among patients with statin-associated immune-mediated necrotizing myopathy (IMNM)."

Journal • Observational data • CNS Disorders • Dyslipidemia • Immunology • Myositis

Inclisiran found Safe and Effective for Lowering LDL in Low-Risk Patients: Study (Medical Dialogues) - P3 | N=350 | V-Mono (NCT05763875) | Sponsor: Novartis Pharmaceuticals | "According to a new study inclisiran, given as a twice-yearly injection, significantly lowers LDL cholesterol in low-risk patients who are not on any lipid-lowering treatment at present...LDL Cholesterol Reduction: Inclisiran reduced LDL cholesterol by 46.5% from baseline; Ezetimibe lowered LDL cholesterol by 11.2%; LDL cholesterol in the placebo group rose by 1.4%; Absolute decreases in LDL cholesterol: Inclisiran: 64.9 mg/dL; Ezetimibe: 17.6 mg/dL; Placebo: 1.3 mg/dL."

P3 data • Cardiovascular • Dyslipidemia

Comparative metabolism of an N-acetylgalactosamine-conjugated small interfering RNA, inclisiran, among various in vitro systems and correlations with in vivo metabolism in rats. (PubMed, Drug Metab Dispos) - "SIGNIFICANCE STATEMENT: This research offers profound insights into the metabolic pathways and characteristics of inclisiran across various in vitro models and in vivo plasma and liver, enhancing our understanding of inclisiran's metabolism. It establishes a critical foundation for selecting appropriate in vitro systems for future studies of other N-acetylgalactosamine-conjugated small interfering RNAs, aiding in the optimization and development of oligonucleotide therapeutics, and thereby advancing the field of RNA-based drug development."

Journal • Preclinical

V-INCLUSION: VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease (clinicaltrials.gov) - P4 | N=130 | Active, not recruiting | Sponsor: Duke University | Recruiting ➔ Active, not recruiting | N=1440 ➔ 130

Enrollment change • Enrollment closed • Atherosclerosis • Cardiovascular • Heart Failure

Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review. (PubMed, J Lipid Atheroscler) - "Novel therapeutic agents, including proprotein convertase subtilisin/kexin type 9 inhibitors, inclisiran, and antisense oligonucleotides such as pelacarsen, have demonstrated promising effects in lowering Lp(a). Given the high burden of cardiovascular disease and ethnic variability in Lp(a) distribution and genetic determinants, routine measurement of Lp(a) could improve risk stratification and therapeutic decision-making. This review summarizes current evidence regarding the epidemiology, genetic background, clinical relevance, and emerging therapeutic strategies targeting Lp(a) in Asian populations, highlighting the need for population-specific thresholds and further research to guide clinical practice."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Ischemic stroke • Myocardial Infarction

2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid. (PubMed, J Lipid Atheroscler) - "This agent modestly increases the incidence of gout and cholelithiasis. For primary and secondary prevention, it may be recommended as a non-first-line agent, either alone or in combination therapy."

Journal • Review • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Gastroenterology • Gout • Inflammatory Arthritis • Rheumatology

TREATMENT WITH INCLISIRAN IN PATIENTS WITH NONFAMILIAL HYPERCHOLESTEROLEMIA AND CHRONIC KIDNEY DISEASE (ERA 2025) - "The first-line therapy for the management of hypercholesterolemia, including in patients with chronic kidney disease, is represented by statins even in combination with ezetimibe. Inclisiran should be considered as a viable therapeutic alternative for the management of pure hypercholesterolemia in patients with chronic kidney disease who are intolerant to statin treatment because it achieves the optimal LDL-cholesterol targets required by actual guidelines without side effects."

Clinical • Chronic Kidney Disease • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Genetic Disorders • Heart Failure • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Evaluating lipid-lowering target adherence in high-risk CKD patients: A retrospective analysis of dyslipidaemia management in a pre-dialysis population (UKKW 2025) - "Combination LLT usage was limited, with 12 patients on statin-ezetimibe and none on bempedoic acid. The median LDL-C was 2.3 mmol/L using Sampson’s method and 2.2 mmol/L with Friedewald’ s formula. Among the cohort, 89% exceeded the <1.4 mmol/L target, and 73.2% and 65% surpassed the <1.8 mmol/L and <2.0 mmol/L thresholds, respectively. LLT was prescribed in 72% of patients, with statins being the most common monotherapy."

Adherence • Retrospective data • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Hypertension • Nephrology • Renal Disease

A Case Series of Heterozygous Familial Hypercholesteremia With PCSK9 Inhibitor Failure (ENDO 2025) - "Evolocumab was switched to alirocumab which initially reduced her LDL-C to 2.65 mmol/L (102.5 mg/dL), but it later rose again. Ezetimibe 10mg daily was added and patient is awaiting approval for inclisiran.CASE 2: An 18-year-old woman with type 1 diabetes and celiac disease was seen in September 2012 for dyslipidemia...Pravastatin 40 mg was started but discontinued due to myalgias...Further research is needed to understand the underlying mechanisms and the likelihood of this occurring in other patients. These cases also highlight the need for ongoing vigilance in patients with high cholesterol and HeFH to ensure optimal cardiovascular protection."

Clinical • Cardiovascular • Celiac Disease • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Immunology • Metabolic Disorders • Musculoskeletal Pain • Pain • Type 1 Diabetes Mellitus

Association of inclisiran initiation on oral antilipemic therapy discontinuation rates (NLA 2025) - "Conclusions Overall, there was a statistically significant decrease in the use of oral antilipemic agents after the initiation of inclisiran, including reduced use of statins, fenofibrates, and ezetimibe. After initiating inclisiran, we see a significant reduction in oral agents, including statins which have known benefit in cardiovascular risk reduction independent of LDL lowering. Upcoming studies evaluating the effect of inclisiran on cardiovascular risk will help to determine if this practice should be continued."

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

Rapid progression of carotid artery stenosis in a postmenopausal patient with untreated familial hypercholesterolemia (NLA 2025) - "The patient was referred to vascular surgery for evaluation and was advised towards medical management with aspirin and lipid-lowering therapy with evolocumab or inclisiran. In particular, ASCVD risk increases following menopause for all women, but is particularly significant in women with FH. Physicians should be aggressive in screening and recommending lipid-lowering therapies for postmenopausal women with FH."

Clinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Developmental Disorders • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders • Peripheral Arterial Disease

Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option. (NLA 2025) - "Methods Based on her history of pancreatitis, we stopped the rosuvastatin 5 mg, and started icosapent ethyl 2 gm BID with gemfibrozil 600 mg twice daily...Ezetimibe 10 gm was added but the patient had muscle pain. Alirocumab 150 mg twice weekly was started but patient developed sinusitis that persisted even on reduced dose...However, more long-term studies are needed to assess the impact on cardiovascular outcomes. Our case demonstrates the presence of multiple options available to treat mixed hyperlipidemia."

Case study • Clinical • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Hypertension • Hypertriglyceridemia • Immunology • Mixed Hyperlipidemia • Musculoskeletal Pain • Otorhinolaryngology • Pain • Pancreatitis • Respiratory Diseases • Sinusitis

Triple hit: Familial hypercholesterolemia, elevated Lp(a), and apoB defect driving early aortic stenosis in a 56-year-old female (NLA 2025) - "Inclisiran was added and using shared decision making, high dose rosuvastatin three times a week and ezetimibe were started. Patients with early onset aortic stenosis should be screened for FH and Lp(a) also. Through shared decision making, a tailored lipid-lowering regimen can individualize therapy in managing complex dyslipidemia and potentially delay or prevent adverse outcomes."

Cardiovascular • Dyslipidemia • Endocrine Disorders • Familial Hypercholesterolemia • Fatigue • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders • Pain • APOB